NLS pharma-1

AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases. The proposed acquisition will enrich AstraZeneca’s growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) […]

Nykode Therapeutics has announced an expansion of the pipeline with a potential first-in-class preclinical oncology vaccine program aimed at preventing and treating colorectal cancer. “The potential first-in-class program reaffirms Nykode’s vision of building a balanced cancer vaccine portfolio. We are excited about the transformative power of our next-generation technology with the potential to reduce the […]

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a US-based clinical-stage biopharma company focused on developing vaccines using a protein virus-like particle (VLP) platform. The proposed acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12, the […]

Herantis Pharma has carried out an offering of new shares in a directed share issue to institutional and other qualified investors. “We thank our existing shareholders, many of whom participated in this directed issue, for their continued support in developing HER-096 as a promising disease-modifying drug candidate for Parkinson’s disease. We are delighted to welcome […]

Calliditas’ partner Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. Everest also announced that, in addition to Nefecon’s approval in mainland China and Macau, it expects a decision on New Drug Application (NDA) […]

The company has announced the acceptance of the supplemental Biologics License Application (sBLA) for a Lucentis (ranibizumab) biosimilar candidate by the US Food and Drug Administration. The regulatory process can therefore be initiated with a Biosimilar User Fee Amendment (BsUFA) goal date of April 21st, 2024, states the company. “Today’s sBLA acceptance marks an important […]